Twist Bioscience (FRA:0ME) EBITDA Margin % : -48.93% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Twist Bioscience EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Twist Bioscience's EBITDA for the three months ended in Mar. 2024 was €-33.9 Mil. Twist Bioscience's Revenue for the three months ended in Mar. 2024 was €69.3 Mil. Therefore, Twist Bioscience's EBITDA margin for the quarter that ended in Mar. 2024 was -48.93%.

Twist Bioscience EBITDA Margin % Historical Data

The historical data trend for Twist Bioscience's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Twist Bioscience EBITDA Margin % Chart

Twist Bioscience Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EBITDA Margin %

Get a 7-Day Free Trial

-183.82

-146.60

-108.75

-103.99

-71.05

Twist Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBITDA Margin %	Get a 7-Day Free Trial															-85.49	-75.75	-56.71	-48.56	-48.93

Competitive Comparison of Twist Bioscience's EBITDA Margin %

For the Diagnostics & Research subindustry, Twist Bioscience's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Twist Bioscience's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Twist Bioscience's EBITDA Margin % falls into.

Twist Bioscience EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Twist Bioscience's EBITDA Margin % for the fiscal year that ended in Sep. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Sep. 2023 )	/	Revenue (A: Sep. 2023 )
	=	-163.179	/	229.667
	=	-71.05 %

Twist Bioscience's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-33.896	/	69.278
	=	-48.93 %

Twist Bioscience (FRA:0ME) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Twist Bioscience EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Twist Bioscience's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Twist Bioscience (FRA:0ME) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Twist Bioscience Corp (FRA:0ME) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

TWST:USA 0ME:Germany

Address

681 Gateway Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.twistbioscience.com

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.

Twist Bioscience (FRA:0ME) Headlines

No Headlines